Plus, Tesla priced its secondary offering and issued a recall of its Model X SUVs in North America, and AstraZeneca posted plunging profits.
Read MoreTesla may be getting all the headlines, but this legacy automaker is the one to watch now.
Read MoreThis retailer may have massive hit this week, but there could be double-digit upside on the horizon. Here’s why.
Read MoreThis drugmaker has a promising treatment for the virus and one expert says the stock’s technical picture makes it a buy now.
Read MorePlus, MGM Resorts’ chairman and CEO steps down as the casino operator withdraws its financial forecast for 2020, and Pepsi and Incyte report earnings.
Read MoreThese 4 energy stocks are primed for massive upside ahead. Here’s why.
Read MoreThis group of stocks has been facing mighty headwinds recently, but the technical picture says the group is gearing up to surge higher.
Read MorePlus, the coronavirus finally has a name, Carnival Cruise Line said that the virus outbreak could dent full-year earnings, and Nissan is suing former Chairman Carlos Ghosn.
Read MorePlus, Fed Chairman Jerome Powell said the central bank is “closely monitoring” the effects of the coronavirus outbreak, and Under Armour shares are sinking after athletic apparel maker said it expects low-single digit sales growth this year.
Read MorePlus, Simon Property Group is acquiring Taubman Centers for $3.6 billion, and Eli Lilly shares are down after a failed trial for its Alzheimer’s drug candidate.
Read MorePlus, the U.S. economy added 225,000 jobs in January, and Myriad Genetics shares are in free fall after it significantly missed on earnings.
Read MoreToday’s 5 market cap leaders are a better bet than their peers from two decades ago. Here’s why.
Read MorePlus, China announced it will halve tariffs on $75 billion worth of U.S. goods, and Yum! Brands warned that it could fall short of its outlook as the coronavirus outbreak weighs on its sales in China.
Read MoreAmazon may be dominating the headlines, but this trillion-dollar club stock is a better bet now. Here’s why.
Read More“Enough is enough,” the analyst wrote. This stock is “too cheap on any reasonable sum-of-the-parts valuation.”
Read More